Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,468.00GBp
12:03pm EDT
Change (% chg)

14.00 (+0.96%)
Prev Close
1,454.00
Open
1,457.50
Day's High
1,471.50
Day's Low
1,455.50
Volume
7,110,474
Avg. Vol
8,779,088
52-wk High
1,745.56
52-wk Low
1,444.00

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.22
Market Cap(Mil.): £71,515.31
Shares Outstanding(Mil.): 4,918.52
Dividend: 19.00
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.33
EPS (TTM): -- -- --
ROI: -- 15.11 14.66
ROE: -- 16.37 13.99

BRIEF-Theravance Biopharma highlights positive results from impact study of Trelegy Ellipta

* Theravance Biopharma highlights positive headline results from impact study of Trelegy Ellipta announced by Glaxosmithkline and Innoviva

Sep 20 2017

BRIEF-GlaxoSmithkline and Innoviva announces positive impact results for Trelegy in COPD

* CO, INNOVIVA REPORT POSITIVE HEADLINE RESULTS FROM STUDY SHOWING SINGLE INHALER TRIPLE THERAPY TRELEGY ELLIPTA REDUCED COPD EXACERBATIONS

Sep 20 2017

GlaxoSmithKline breathes easier as U.S. approves triple lung drug

LONDON U.S. regulators have approved GlaxoSmithKline's three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair.

Sep 19 2017

UPDATE 1-GlaxoSmithKline breathes easier as U.S. approves triple lung drug

* CEO sees it as one of three "critical" new drug launches (Adds detail on competition, analyst reaction, shares)

Sep 19 2017

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

Sep 18 2017

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

Sept 18 GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

Sep 18 2017

France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

PARIS French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said.

Sep 15 2017

France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

PARIS, Sept 15 French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said.

Sep 15 2017

BRIEF-GSK gets EU greenlight for self-injectable version of lupus drug

* GSK RECEIVES CHMP POSITIVE OPINION FOR SELF-INJECTABLE FORMULATION OF BENLYSTA FOR SYSTEMIC LUPUS ERYTHEMATOSUS

Sep 15 2017

GSK's three-in-one inhaler gets positive opinion from EU agency

GlaxoSmithKline said on Friday that a European Medicines Agency (EMA) panel has recommended the company's three-in-one inhaled lung drug.

Sep 15 2017

Earnings vs. Estimates